Form 4 holding
COO, and President, Athenex Pharmaceutical Division.
Athenex, Inc.
- Security class
- Common Stock
- Shares / value
- 245,943
- Estimated value
- $334,482
- Report date
- 03 Aug 2022
- Price
- $1.36
- Ownership
- Direct
Jeffrey Yordon
Insider Reports History
- Latest reporting-owner signature
-
/s/Staci Holquist, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Jeffrey Yordon
Form 4 holding
COO, and President, Athenex Pharmaceutical Division.
Athenex, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 150,000
- Estimated value
- Report date
- 03 Aug 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
Form 4 holding
COO, and President, Athenex Pharmaceutical Division.
Athenex, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 37,500
- Estimated value
- Report date
- 03 Aug 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
Insider Reports Filed by Jeffrey Yordon
4
Athenex, Inc.
- Report period
- 03 Aug 2022
- Transactions
- 3
- Transaction value
- -$2,127
- Accepted by SEC
- 15 Aug 2022, 17:34
- Role
- COO, and President, Athenex Pharmaceutical Division.
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 20 Jul 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jul 2022, 17:40
- Role
- COO, and President, Athenex Pharmaceutical Division. Exhibit List: Exhibit 24.1 - Power of Attorney
- Next action
- Open filing details
4
Athenex, Inc.
- Report period
- 03 Aug 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Aug 2021, 16:49
- Role
- COO, and President, Athenex Pharmaceutical Division.
- Next action
- Open filing details